{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-25-001930","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.946648+00:00","generated_at":"2026-05-17T01:07:03.547281+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Artelo Biosciences issues $690K convertible notes and warrants to investors including directors","bullets":["Issued convertible notes aggregating $690,154.69 principal to investors, converting May 2025 notes.","Notes bear 12% interest (20% on default), mature ~April 28, 2026, convertible at $3.40/share.","Warrants to purchase 438,182 shares of common stock at $3.40 per share, exercisable for 5 years.","Directors Connie Matsui ($110,842), Tamara Favorito ($19,793), and CEO Gregory Gorgas ($27,710) participated."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-25-001930","json":"https://secwatch.observer/filing/0001640334-25-001930.json","markdown":"https://secwatch.observer/filing/0001640334-25-001930.md","text":"https://secwatch.observer/filing/0001640334-25-001930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001930/0001640334-25-001930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001930/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:07:03.547281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29dff323cbd27d417bb4b010d11a978f9ca8cb51","claim":"ARTELO BIOSCIENCES, INC. incurred convertible notes of $690,154.69 at 12% per annum maturing six months after the closing of the Notes Offering.","evidence_excerpt":"On October 28, 2025, Artelo Biosciences, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) pursuant to which it issued and sold to certain investors (the “ Investors ”), and the Investors purchased (by converting all or a portion of the unconverted “Voluntary Conversion” portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the “ Notes ”) to the Investors in an aggregate principal amount of $690,154.69;","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001930/0001640334-25-001930-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$690,154.69"},{"label":"Rate","value":"12% per annum"},{"label":"Maturity","value":"six months after the closing of the Notes Offering"},{"label":"Event","value":"incurrence"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}